Table 4—

Per cent concordance between tests andκ coefficients

Patient groupTST versus T-SPOT.TBTST versus QFG-ITQFG-IT versus T-SPOT.TB
Concordance %κ (sem)Concordance %κ (sem)Concordance %κ (sem)
All patients73.50.46 (0.07)78.50.57 (0.07)88.00.75 (0.075)
Active TB#
 All71.60.42 (0.11)80.50.61 (0.11)82.70.66 (0.11)
 Definite50.0-0.17 (0.14)86.40.49 (0.21)66.70.15 (0.11)
 Probable79.40.59 (0.17)75.00.5 (0.16)87.50.74 (0.17)
 Definite and probable67.90.34 (0.13)79.30.13 (0.13)79.30.56 (0.13)
 Possible80.0-0.11 (0.20)83.3-0.09 (0.20)90.00.45 (0.21)
LTBI
 All75.00.49 (0.09)77.00.53 (0.09)92.00.82 (0.09)
 BCG74.00.48 (0.12)76.00.51 (0.11)90.00.78 (0.12)
 No BCG77.00.56 (0.16)73.00.5 (0.16)96.70.93 (0.18)
  • TST: tuberculin skin test; QFG-IT: QuantiFERON-TB Gold In-tube system (Cellestis, Carnegie, Australia); TB: tuberculosis; LTBI: latent TB infection; BCG: bacillus Calmette–Guérin. T-SPOT.TB is manufactured by Oxford Immunotec, Abingdon, UK. #: n = 91; : n = 118.